| 3177 |
1633: Increase in inflammation |
2119: Insulin resistance, increased |
Apr 9, 2024 |
Apr 9, 2024 |
1 AOP
|
| 1904 |
1632: Increase in RONS |
1194: Increase, DNA Damage |
May 7, 2019 |
May 8, 2019 |
3 AOPs
|
| 1906 |
1632: Increase in RONS |
1492: Tissue resident cell activation |
May 7, 2019 |
May 9, 2019 |
2 AOPs
|
| 2331 |
1632: Increase in RONS |
1861: D1 protein deactivation |
Apr 11, 2021 |
Apr 11, 2021 |
None
|
| 2337 |
1632: Increase in RONS |
1770: Decrease, MMP |
Apr 11, 2021 |
Apr 11, 2021 |
None
|
| 2798 |
1632: Increase in RONS |
2073: methemocyanin formation (decrease overall oxygen binding capacity) |
Nov 16, 2022 |
Nov 16, 2022 |
1 AOP
|
| 3268 |
1632: Increase in RONS |
1392: Oxidative Stress |
Jul 4, 2024 |
Jul 4, 2024 |
1 AOP
|
| 3565 |
1632: Increase in RONS |
1767: Increase, Protein oxidation |
Aug 13, 2025 |
Aug 13, 2025 |
None
|
| 3566 |
1632: Increase in RONS |
1445: Increase, LPO |
Aug 13, 2025 |
Aug 13, 2025 |
None
|
| 3567 |
1632: Increase in RONS |
1634: Increase, Oxidative DNA damage |
Aug 13, 2025 |
Aug 13, 2025 |
None
|
| 1795 |
1553: Increase mutations |
1555: Increase cell proliferation |
Dec 19, 2018 |
Dec 19, 2018 |
None
|
| 1800 |
1553: Increase mutations |
1556: Increase, lung cancer |
Dec 19, 2018 |
Dec 19, 2018 |
None
|
| 1900 |
1553: Increase mutations |
1182: Increase, Cell Proliferation (Epithelial Cells) |
May 7, 2019 |
May 7, 2019 |
None
|
| 3237 |
1553: Increase mutations |
885: Increase, Cancer |
May 28, 2024 |
May 28, 2024 |
1 AOP
|
| 2023 |
1713: Increase of autoantibody production |
1714: Exacerbation of SLE |
Dec 29, 2019 |
Aug 14, 2020 |
1 AOP
|
| 3564 |
2339: Increase of intracellular copper |
1632: Increase in RONS |
Aug 13, 2025 |
Aug 13, 2025 |
None
|
| 3571 |
2339: Increase of intracellular copper |
2340: Oligomerisation of DLAT |
Aug 13, 2025 |
Aug 13, 2025 |
1 AOP
|
| 3574 |
2339: Increase of intracellular copper |
2342: Loss of Fe-S clusters |
Aug 13, 2025 |
Aug 13, 2025 |
1 AOP
|
| 2022 |
1712: Increase of Th2 cells producing IL-4 |
1713: Increase of autoantibody production |
Dec 29, 2019 |
Aug 14, 2020 |
1 AOP
|
| 2799 |
2073: methemocyanin formation (decrease overall oxygen binding capacity) |
2074: Decrease overall oxygen binding capacity (methemocyanin formation) |
Nov 16, 2022 |
Nov 16, 2022 |
1 AOP
|
| 2800 |
2073: methemocyanin formation (decrease overall oxygen binding capacity) |
2075: Hemocyanin Bohr effect decrease |
Nov 16, 2022 |
Nov 16, 2022 |
1 AOP
|
| 2067 |
1743: Increase plasma Ang II |
1745: Increase,collagen synthesis |
Mar 17, 2020 |
Mar 17, 2020 |
None
|
| 2138 |
1743: Increase plasma Ang II |
68: Accumulation, Collagen |
May 15, 2020 |
May 15, 2020 |
None
|
| 2435 |
1743: Increase plasma Ang II |
1852: Increased Ang II type 1 receptor (AT1R) |
Jul 13, 2021 |
Jul 13, 2021 |
1 AOP
|
| 398 |
416: Increase proliferation, Leydig cell |
415: Hyperplasia, Leydig cell |
Nov 29, 2016 |
Dec 3, 2016 |
1 AOP
|